Hetrombopag for low platelets after chemo in acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a medication called hetrombopag, which helps raise platelet counts. It's for people with acute myeloid leukemia who have low platelets after intensive chemotherapy and are in remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between the ages of 18 and 70.
- You have acute myeloid leukemia (not a specific subtype) and are currently in complete remission.
- You have received at most one course of intensive consolidation chemotherapy and will continue with more intensive chemo.
- Your expected survival is at least 3 months, and you are physically able to undergo at least 2 more chemo cycles.
- You have not had a blood clot, heart attack, or stroke in the past 6 months.
- You have not used platelet-boosting drugs (like romiplostim or eltrombopag) in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication, hetrombopag, to see if it can safely raise platelet counts in people with gynecologic cancers whose platelets drop too low from chemotherapy or other cancer treatments. It may help them continue their cancer therapy without delays or bleeding risks.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This study tests a medicine called hetrombopag that may help raise your platelet count after chemotherapy for advanced lung cancer. It aims to prevent dangerously low platelet levels so you can continue your cancer treatment more safely.
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
Hear when a new Chemotherapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.